The University of Southampton
University of Southampton Institutional Repository

Pathogenesis of fibrosing colonopathy: the role of methachrylic acid copolymers.

Pathogenesis of fibrosing colonopathy: the role of methachrylic acid copolymers.
Pathogenesis of fibrosing colonopathy: the role of methachrylic acid copolymers.
Fibrosing colonopathy is a serious bowel disorder which was first seen in 1991 in patients with cystic fibrosis treated with high doses of pancreatic enzyme supplements. Epidemiological evidence from two case-control studies, temporal data and direct experimental evidence support the conclusion that there is a causal relationship between the disease and intake of high doses of the excipient, methacrylic acid copolymer, which is used to coat certain brands of pancreatic enzyme. A high intake of lipase, the active ingredient in pancreatic enzymes, is not a risk factor for fibrosing colonopathy in the absence of methacrylic acid copolymer. Excipients may be toxic if used in new patient populations such as children and in doses exceeding the safe levels predicted by animal toxicology.
fibrosing colonopathy, pancreatic enzymes, cystic fibrosis, methacrylic acid copolymer
1053-8569
377-384
Prescott, Philip
cf0adfdd-989b-4f15-9e60-ef85eed817b2
Bakowski, Marie T.
5ccf108b-45b1-49cc-8600-765ec86a9c07
Prescott, Philip
cf0adfdd-989b-4f15-9e60-ef85eed817b2
Bakowski, Marie T.
5ccf108b-45b1-49cc-8600-765ec86a9c07

Prescott, Philip and Bakowski, Marie T. (1999) Pathogenesis of fibrosing colonopathy: the role of methachrylic acid copolymers. Pharmacoepidemiology and Drug Safety, 8 (6), 377-384. (doi:10.1002/(SICI)1099-1557(199910/11)8:6<377::AID-PDS448>3.0.CO;2-C).

Record type: Article

Abstract

Fibrosing colonopathy is a serious bowel disorder which was first seen in 1991 in patients with cystic fibrosis treated with high doses of pancreatic enzyme supplements. Epidemiological evidence from two case-control studies, temporal data and direct experimental evidence support the conclusion that there is a causal relationship between the disease and intake of high doses of the excipient, methacrylic acid copolymer, which is used to coat certain brands of pancreatic enzyme. A high intake of lipase, the active ingredient in pancreatic enzymes, is not a risk factor for fibrosing colonopathy in the absence of methacrylic acid copolymer. Excipients may be toxic if used in new patient populations such as children and in doses exceeding the safe levels predicted by animal toxicology.

This record has no associated files available for download.

More information

Published date: 1999
Keywords: fibrosing colonopathy, pancreatic enzymes, cystic fibrosis, methacrylic acid copolymer
Organisations: Statistics

Identifiers

Local EPrints ID: 29981
URI: http://eprints.soton.ac.uk/id/eprint/29981
ISSN: 1053-8569
PURE UUID: 0b41a31b-009b-4e8d-a3da-5cc560672f6d

Catalogue record

Date deposited: 19 Mar 2007
Last modified: 15 Mar 2024 07:36

Export record

Altmetrics

Contributors

Author: Philip Prescott
Author: Marie T. Bakowski

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×